Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
PipCast®
PTE
Trade Marks
Webinars

GSK DREAMM-7 Phase III Trials Demonstrate Superior Results with Blenrep Combination

Feb 5, 2024

On 5 February 2024, Glaxo Smith Kline (GSK) announced results from an interim analysis of its DREAMM-7 phase III trial.  The trial compared two treatment combinations, namely: 

  • Blenrep® Combination: Blenrep® (belantamab mafodotin) +  BorDex® (bortezomib plus dexamethasone); and 
  • Daratumumab combination: daratumumab + BorDex® (bortezomib plus dexamethasone) 

The Blenrep® Combination showed: a) 59% further reduction in risk of disease progression or death, b) 23.2 more months of median progression-free survival, and c) 43% reduction in risk of death.